# Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

> **NCT03271047** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 75 (actual)

## Conditions studied

- MSS
- RAS-mutant Colorectal Cancer

## Interventions

- **DRUG:** binimetinib
- **DRUG:** nivolumab
- **DRUG:** ipilimumab

## Key facts

- **NCT ID:** NCT03271047
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-18
- **Primary completion:** 2020-10-13
- **Final completion:** 2021-02-25
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2022-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03271047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03271047, "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03271047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*